Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.55 |
| ▸ | HTT | P42858 | 4/20 | 0.55 |
| ▸ | TP53 | P04637 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KCNMA1 | Q12791 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9469934 | 0.79 | AR (0.43) | LMNAHTTGAAHSD17B10HPGD | |
| SCHEMBL9469154 | 0.78 | CETP (0.43) | LMNAHTTGAAHSD17B10KDM4E | |
| SCHEMBL13078480 | 0.74 | HCAR2 (0.49) | NPC1GAAKDM4EMAPK1RAB9A | |
| SCHEMBL13078416 | 0.74 | ALOX15 (0.42) | GAAMAPK1MAPTSMN1; SMN2 | |
| SCHEMBL28212257 | 0.73 | AR (0.48) | NPC1GAAHSD17B10KDM4EHPGD | |
| SCHEMBL845142 | 0.73 | LMNA (1.00) | LMNAHTTTP53NPC1GAA | |
| SCHEMBL13078178 | 0.73 | MEN1 (0.47) | LMNANPC1GAAKDM4EMAPK1 | |
| SCHEMBL28842439 | 0.72 | LMNA (0.96) | LMNAHTTTP53NPC1GAA | |
| SCHEMBL28842312 | 0.72 | LMNA (0.96) | LMNAHTTTP53NPC1GAA | |
| SCHEMBL7678596 | 0.72 | LMNA (0.88) | LMNAHTTTP53NPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2039683-B1 | Vasculostatic agents and methods of use thereof | TARGEGEN INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100278811-A1 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN INC. | 2010-11-04 | — | — | US | disclosed |
| EP-2039683-A2 | Vasculostatic agents and methods of use thereof | Targegen, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-1549614-A4 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN INC (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20070208019-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. | 2007-09-06 | — | — | US | disclosed |
| US-7208493-B2 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20050282814-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. (US) | 2005-12-22 | — | — | US | disclosed |
| EP-1549614-A2 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | Targegen, Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040167198-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. | 2004-08-26 | — | — | US | disclosed |
| WO-2004030635-A2 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN, INC. (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | RBP1, RBP4, VCAM1 | LMNA 3256/4885HTT 3760/4885TP53 1631/4885 |
| US-20050282814-A1 | Vasculostatic agents and methods of use thereof | RBP1, RBP4, VCAM1 | LMNA 3256/4885HTT 3760/4885TP53 1631/4885 |
| US-20070208019-A1 | Vasculostatic agents and methods of use thereof | RBP1, RBP4, VCAM1 | LMNA 3256/4885HTT 3760/4885TP53 1631/4885 |
| US-20100278811-A1 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | RBP1, RBP4, VCAM1 | LMNA 3256/4885HTT 3760/4885TP53 1631/4885 |
| US-20040167198-A1 | Vasculostatic agents and methods of use thereof | RBP1, RBP4, VCAM1 | LMNA 3256/4885HTT 3760/4885TP53 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.